Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebipenem-pivoxil vs Ceftriaxone for Shigellosis in Children
NCT05121974Phase 2Completed
- Sponsor
- icddr,b
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tebipenem in shigellosis (2 arms), sponsored by icddr,b. Primary endpoint: Clinical failure at Day 3. Started Aug 2022; status: completed.
02
Drugs
tebipenem
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT05121974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121974.